According to the ICC 2022 classification, 24 (42.1%) patients were classified as having AML with myelodysplasia related gene mutations/cytogenetics, 14 (24.6%) AML with mutated NPM1, 3 (5.3%) AML with mutated TP53, 1 (1.8%) AML with t (9, 11)(p21.3;q23.3)/MLL::KMT2A, and 15 (26.3%) AML not otherwise specified. This evidence concerns the gene KMT2A and acute myeloid leukemia.